By the Top Tier Newswire AI Desk · September 21, 2026 at 2:10 PM ET · reviewed against 8 wire stories
MODERNA INC (MRNA) is up +14.32% in the latest session. Our newswire has captured 8 stories on MRNA across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Moderna Inc (NASDAQ:MRNA) shares surged 14.32% to $176.10 on Friday, driven by the company's announcement that late-breaking Phase 3 melanoma data for its investigational mRNA therapy, intismeran autogene, will be presented at the ESMO 2026 Congress. The data is scheduled for a high-profile Presidential Symposium, signaling strong progress in Moderna’s oncology pipeline. The news has drawn heightened investor attention, with the stock hitting an intraday high of $176.26.
What Happened
Moderna confirmed that three abstracts on intismeran autogene were accepted for presentation at ESMO 2026, including the Phase 3 melanoma data. The company also announced a scheduled investor webcast on October 24 to discuss the findings. The data is part of a broader clinical development program exploring the personalized therapy in pancreatic and lung cancers. This comes after the stock opened with a 1.8% gap up from the previous close and continued to climb throughout the session. The stock’s performance reflects optimism about the potential of intismeran to become a key product in the growing mRNA-based cancer treatment market.
What The Data Shows
The stock has moved up 18.8% over the last eight sessions, from $135.66 to $161.14, and has printed 28 fresh 52-week highs on September 21. Trading volume was 11.4 million shares, or 0.8 times the 3-month daily average. Options activity showed heavy call buying, with $24.2 million in call premiums compared to $302,000 in put premiums. The largest single options print totaled $7.1 million. Despite recent insider sales totaling $49.2 million over the last 90 days, the stock’s upward momentum suggests strong market confidence in the upcoming data presentation.
What To Watch
Investors will be closely watching the October 24 webcast for further details on the Phase 3 melanoma data and its implications for the broader clinical program. The results could influence future development timelines and investor sentiment for Moderna’s oncology portfolio.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MRNA · today's session (5-min) · +11.98% vs prior close · updated 7:01 PM ETAI sentiment, last 36h · averaged over 8 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoStocktwits NewsBULLISH 64Product/PR
Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’
Moderna will showcase detailed melanoma results for Intismeran at ESMO, alongside data and trial updates exploring the personalized therapy in pancreatic and lung cancers.
5h agoBarron'sBULLISH 67Product/PR
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
7h ago24/7 Wall St.BULLISH 73Product/PR
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Moderna (NASDAQ:MRNA) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at the European Society for Medical Oncology congress in Madrid. The stock is at $167.90, up 9% in Monday morning […]
7h agoMarketChameleonBULLISH 67Product/PR
Moderna spotlights Phase 3 melanoma data at ESMO 2026, setting up an October 24 investor webcast
September 21, 2026
Moderna said three abstracts on intismeran autogene were accepted for presentation at ESMO Congress 2026, including late-breaking Phase 3 melanoma data selected for a Presidential Symposium. The company also scheduled an investor webcast for October 24, following the featured melanoma presentation, and highlighted additional program activity in pancreatic cancer and early-stage NSCLC.
8h agoStockTitanBULLISH 63Product/PR
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
The three presentations include phase 3 melanoma and NSCLC studies plus a phase I pancreatic cancer study. A webcast is set for Oct. 24.
9h agoInvesting.com MarketsBULLISH 55General
Why is Moderna stock surging today?
Why is Moderna stock surging today?
15h agoPR NewswireBULLISH 55General
Yann LeCun, Bob Langer, Jens Nielsen and Fabian Theis Join Cellular Intelligence Scientific Advisory Board
Turing Award Laureate, Moderna Co-Founder, BioInnovation Institute CEO and Helmholtz Munich Computational Health Director to Advise on Decoding the Logic that Governs How Cells Change and Carrying That Knowledge Into Medicine BOSTON, Sept. 21, 2026 /PRNewswire/ -- Cellular Intelligence,...
20h agoFortuneBULLISH 63Product/PR
Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug
CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →